News

WASHINGTON, DC, November 13, 2024 — A new report commissioned by Arnold & Porter, based on a survey of 100 senior executives and department heads from biopharmaceutical, digital health, diagnostics, and medical device companies, shows that artificial intelligence (AI) adoption is accelerating across the industry as companies implement it to accelerate product discovery and development, optimize manufacturing and the supply chain, improve marketing and sales strategies, and more.  

The 2024 edition of LMG Life Sciences recognized Arnold & Porter in its annual directory of life science legal recommendations. 

NEWARK, N.J., and NEW YORK, March 25, 2024 — Arnold & Porter is pleased to announce the continuing growth of its Newark office with the arrival of Lee Cortes, former Executive Assistant United States Attorney for the District of New Jersey. Cortes has joined the firm’s White Collar Defense & Investigations practice as partner, resident in the firm’s Newark and New York offices.

BOSTON, November 16, 2023 — Arnold & Porter announced today that veteran white collar defense attorney and former Assistant U.S. Attorney Giselle Joffre has joined the firm’s White Collar Defense & Investigations practice as a partner, resident in Boston. 

Washington, D.C., November 6, 2023 — Arnold & Porter announced today that Philip Desjardins, former FDA Center for Devices and Radiological Health Associate Director for Policy and Johnson & Johnson Vice President of Global Regulatory Affairs, has rejoined the firm’s Life Sciences and Healthcare Regulatory practice as a partner, resident in Washington, D.C.

BOSTON, September 20, 2023 — Arnold & Porter announced today that it has opened an office in Boston with a focus on life sciences and health care transactions, litigation, regulatory counseling, and government investigations. Arnold & Porter is globally renowned for decades of excellence in its legal work for the life sciences industry, including numerous Boston-based biotech companies.